NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.

Publication Type:

Journal Article

Source:

Journal of the National Comprehensive Cancer Network : JNCCN, Volume 15, Issue 9, p.1091-1102 (2017)

Abstract:

The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. However, the management of relapsed or refractory (R/R) ALL remains challenging and prognosis is poor. The NCCN Guidelines for ALL provide recommendations on standard treatment approaches based on current evidence. These NCCN Guidelines Insights summarize treatment recommendations for R/R ALL and highlight important updates, and provide a summary of the panel's discussion and underlying data supporting the most recent recommendations for R/R ALL management.